Quantidoc and AlgiSys have announced their cross-border partnership during the Aqua Nor Conference, supporting the Norwegian Ministry of Aquaculture’s mandate to enhance fish health and welfare.

Quantidoc, a barrier health company located in Bergen, has developed technology that is the industry standard for quantifying, verifying and maintaining the health and robustness of fish frontline barriers.

Likewise, AlgiSys Aqua Ltd, based in Edinburgh, Scotland, is developing a functional aquafeed ingredient made from EPA-rich omega-3 microalgae with protein. The main goal is that this ingredient shall strengthen those frontline fish barriers and improve overall fish health while increasing the EPA omega-3 content of fish.

Jacob Grieg Eide, co-owner and CBDO of Quantidoc noted: “Fish farming is facing an alarming rate of disease and mortality on a global scale. In partnership with AlgiSys, our combined technologies directly support the Norwegian government’s new mandate, which focuses on improving fish health and welfare in aquaculture.”

In the same way, Roger Frank, CEO of AlgiSys Aqua Ltd, added: “Our partnership with Quantidoc is powerful. With our functional feed aquafeed ingredient, EPA-rich omega-3 microalgae, we can improve barrier health, which we can measure and quantify through VERIBARR, while also increasing the EPA omega-3 content of fish.” Frank concluded: “We are deeply appreciative of the Scottish Development Agency’s support and our partnership with Quantidoc. Together, we can increase the sustainability of the industry while improving fish health and industry economics.”